Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Meningioma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2016, provides an overview of the Meningioma (Oncology) pipeline landscape. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Meningioma. Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Meningioma Overview 6 Therapeutics Development 7 Pipeline Products for Meningioma - Overview 7 Pipeline Products for Meningioma - Comparative Analysis 8 Meningioma - Therapeutics under Development by Companies 9 Meningioma - Therapeutics under Investigation by Universities/Institutes 10 Meningioma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Meningioma - Products under Development by Companies 13 Meningioma - Products under Investigation by Universities/Institutes 14 Meningioma - Companies Involved in Therapeutics Development 15 Arno Therapeutics Inc 15 AstraZeneca Plc 16 Boehringer Ingelheim GmbH 17 GlaxoSmithKline Plc 18 Novartis AG 19 Pharma Mar SA 20 Progenics Pharmaceuticals Inc 21 Meningioma - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 afatinib dimaleate - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 AR-42 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Edotreotide Labeled Yttrium 90 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 GSK-2256098 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 HXR-9 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 pasireotide - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 trabectedin - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 vistusertib - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Meningioma - Dormant Projects 63 Meningioma - Discontinued Products 64 Meningioma - Product Development Milestones 65 Featured News & Press Releases 65 Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma 65 Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe 65 Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Meningioma, H2 2016 7 Number of Products under Development for Meningioma - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Meningioma - Pipeline by Arno Therapeutics Inc, H2 2016 15 Meningioma - Pipeline by AstraZeneca Plc, H2 2016 16 Meningioma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 17 Meningioma - Pipeline by GlaxoSmithKline Plc, H2 2016 18 Meningioma - Pipeline by Novartis AG, H2 2016 19 Meningioma - Pipeline by Pharma Mar SA, H2 2016 20 Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Meningioma - Dormant Projects, H2 2016 63 Meningioma - Discontinued Products, H2 2016 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.